Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unrese...
Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )
27 Sep 2022
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced br...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
21 Sep 2022
ESMO 2022: Breast and ovarian trial analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
14 Sep 2022
ERMES study suggests a strategy of de-escalation with only cetuximab in first li...
Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy
ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC ( Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy )
14 Sep 2022
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )
14 Sep 2022
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible loca...
Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York Cit...
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )
14 Sep 2022
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-li...
Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia
Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC ( Dr Marcin Dzienis - Gold Coast University Hospital, Southport, Australia )
14 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
Ideal duration of androgen deprivation therapy with post-operative radiotherapy ...
Prof Chris Parker - Institute of Cancer Research, Sutton, UK
Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )
12 Sep 2022
Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma...
Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA
Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy ( Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
A new era of early cancer detection with blood test may change cancer screening ...
Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA
A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squ...
Dr Silvia Novello - University of Turin, Turin, Italy
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
11 Sep 2022